Main Image

  • Posted Monday December 20, 2021

TGen helps develop analysis tool, leading to more-accurate evaluation of new brain tumor treatments and individual estimates of survival

‘Nomograms’ accounting for sex differences in the design of clinical trials should help deliver new precision treatments to glioblastoma patients

PHOENIX, Ariz. — Dec. 20, 2021 — An international team of scientists, including those at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, devised a tool that could help design more successful clinical trials for new brain-tumor drug treatments.

Findings from an international study published in the Journal of Neuro-Oncology suggest that a tool called a nomogram could help predict the likely survival time of individual patients with glioblastoma, the most common malignant brain cancer in adults, with an average survival of less than two years.

However, survival times vary among patients because of numerous factors, including: age, where the tumor is located, how much of the tumor is removed through surgery and — most importantly in this study — the patient’s sex.

It is now well established that males are more likely to develop glioblastomas compared to females, and that females respond to treatments at almost twice the rate of males. If these factors are not considered in selecting clinical trial participants, the results could be skewed because of an imbalance among those receiving a new treatment and those receiving the current standard-of-care. Faulty results could lead to the approval of a drug that has little or no value, or the rejection of a drug that actually could benefit particular patients.

“The more balanced the experimental and control treatment arms are, the higher the likelihood that researchers draw efficacy conclusions that stand up in routine clinical use,” said Michael Berens, Ph.D., Professor and Director of TGen’s Cancer and Cell Biology Division, and one of the study’s authors.

“If we miss some active drugs because we stacked the deck against ourselves, it would be tragic,” said Dr. Berens, who also is a TGen Deputy Director of Institutional Initiatives. “You must find subsets of patients with better chances of benefitting from a specific, new treatment. Get them the drug. That’s called precision medicine.”

Study based on more than 1,300 patients

In creating a nomogram for glioblastoma, the study examined the outcomes in two clinical trials among 1,359 patients newly-diagnosed with glioblastoma.

“The differences in the nomograms by sex shown here indicates that the prognosis of females and males may be different, and that these nomograms are useful tools for estimating patient-level survival probabilities,” the study concludes, recommending that additional research be conducted to better characterize the exact biological mechanisms underlying sex differences in glioblastoma.

Nomograms for other cancers are used in oncology and medicine to generate the probability of clinical events by integrating variables to produce biological and clinical models that help with treatment decisions. The predictive nomogram for glioblastoma developed through this study can be found at:

“Nomograms for glioblastoma fill a significant unmet need in the design of clinical trials of new treatments for this deadly brain cancer, for which patients have few treatment options,” said Jill Barnholtz-Sloan, Ph.D., the study’s senior author, previously the Sally S. Morley Designated Professor for Brain Tumor Research at Case Western Reserve University School of Medicine, and Director for Research Health Analytics at University Hospitals of Cleveland (both in Cleveland, Ohio).

“Despite advances in both treatment and biological understanding, the prognosis for patients with glioblastoma remains poor and we do not understand the underlying biological mechanisms for these known sex differences in incidence and survival,” said Dr. Barnholtz-Sloan.

Also contributing to this study were: Barrow Neurology Clinics Accruals, Arizona Oncology Services Foundation, Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Penn State University, Washington University (St. Louis), University of Texas-MD Anderson Cancer Center, Thomas Jefferson University Hospital, Intermountain Medical Center, USON-Willamette Valley Cancer Center, University of Wisconsin School of Medicine and Public Health, American College of Radiology, Miami Cancer Institute, Tel-Aviv Medical Center (Israel), and McGill University Health Center (Canada).

The study — Independently validated sex‐specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 — was supported by grants from the National Cancer Institute, Merck & Co. Inc., and Genentech BioOncology.

# # #

About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases:  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: Follow TGen on FacebookLinkedIn and Twitter @TGen.

Media Contact:
Steve Yozwiak
TGen Senior Science Writer
[email protected]

Media Contact

RSS Feed